Pharmaceutical Technology

MARCH 1, 2023

The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.

RNA 147

RNA Vaccination Vaccine Genetics 147

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

NOVEMBER 2, 2023

While things may have slowed down a little since the rapid approvals of the COVID-19 vaccines, the excitement around RNA-LNP is still going strong.

RNA 130

RNA Manufacturing Vaccination Vaccine 130

Pharmaceutical Technology

APRIL 27, 2023

Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.

RNA 130

RNA Medicine Gene Therapy Gene 130

Drug Discovery World

SEPTEMBER 12, 2022

As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. The post New solution to boost RNA drug development appeared first on Drug Discovery World (DDW).

RNA 52

RNA Development Gene Therapy Drugs 52

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccination 147

Vaccination Vaccine Development Gene Therapy 147

STAT News

NOVEMBER 24, 2022

An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Scienmag

JULY 6, 2022

Army scientists and industry partners were among the first to demonstrate that messenger RNA (mRNA)—the technology recently used in COVID-19 vaccines and others—could also be used to develop treatments for infectious diseases. Credit: Study: USAMRIID / […].

RNA 81

RNA Development Scientist Vaccination 81

Roots Analysis

NOVEMBER 6, 2023

RNA-based therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. The below figure presents the distribution of next generation RNA-based therapeutics and RNA-based vaccines, based on type of molecule.

RNA 40

RNA Vaccination Vaccine Clinical Trials 40

Drug Discovery World

JANUARY 10, 2023

Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. . Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells. .

RNA 52

RNA Development Gene Therapy Protein 52

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 16, 2022

The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.

Vaccination 175

Vaccination Vaccine RNA Development 175

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharma Mirror

MARCH 29, 2022

NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.

Manufacturing 130

Manufacturing Production Development RNA 130

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.

RNA 98

RNA Genome Genomics Engineer 98

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

Vaccination 289

Vaccination Vaccine Gene Therapy RNA 289

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineer 262

Engineer Vaccination Vaccine Clinical Trials 262

pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 billion, consummating a relationship that first started in 2018 and spanned a range of mRNA-based vaccines for infectious diseases. billion, including $150 million upfront.

RNA 95

RNA Vaccination Vaccine Clinical Trials 95

pharmaphorum

JANUARY 13, 2023

Bringing Next Generation RNA Therapies to Patients Faster. Expect exclusive data from KOLs on the most recent developments in circRNAs , saRNAs , eRNAs & tRNAs therapies. The post 2nd Next Generation RNA Therapeutics Summit appeared first on. Explore the full event guide here – [link].

RNA 52

RNA Vaccination Vaccine Development 52

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccination Vaccine Sales 98

Drug Discovery World

JUNE 7, 2023

Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Currently there are no approved drugs or vaccines for neither Hendra nor Nipah virus infections available, underlining an urgent need for accelerated research and development.

RNA 52

RNA Vaccination Vaccine Antibody 52

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccination 52

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.

RNA 52

RNA Medicine Engineer Drugs 52

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

VirTrial

OCTOBER 25, 2023

Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participation follow-up periods, multiphase designs, and critical data management needs. In recent years, Signant has been a part of more than 95 vaccine studies involving 140,000+ patients in more than 30 countries.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Pharmaceutical Technology

JUNE 30, 2022

HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

Bio Pharma Dive

OCTOBER 6, 2022

A new agreement with the Australian government will bring messenger RNA research and manufacturing capabilities to the country, adding to the COVID-19 vaccine developer’s global expansion efforts.

RNA 194

RNA Manufacturing Vaccination Vaccine 194

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Pharmaceutical Technology

MARCH 23, 2023

China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. The independently developed SYS6006 vaccine has been designed to target some major Omicron variants. efficacy after 14 to 28 days.

Vaccination 130

Vaccination Vaccine Gene Therapy Clinical Trials 130

Drug Discovery World

OCTOBER 2, 2023

This eBook sponsored by DNA Script explores the advances and breakthroughs taking place within vaccines and virology.

Vaccination 52

Vaccination Vaccine RNA DNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Pharmaceutical Technology

AUGUST 24, 2022

Mode rna has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorization (EUA) for mRNA-1273.222, its BA.4/BA.5 5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above.

Vaccination 130

Vaccination Vaccine Gene Therapy Antibody 130

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 52

RNA Engineer Life Science Drugs 52

BioSpace

APRIL 11, 2021

Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.

Vaccination 142

Vaccination Vaccine RNA Development 142

STAT News

JANUARY 19, 2023

And do normal people care about messenger RNA? Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involving a Scientologist CEO and secretive investor seeking redemption after the worst trade of his life. Where do new drugs come from?

Vaccination 115

Vaccination Vaccine Life Science RNA 115